Asset Details
Do you wish to reserve the book?
Trichosporon asahii causing subcutaneous mycoses in an immunocompetent patient: case report and a minireview
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trichosporon asahii causing subcutaneous mycoses in an immunocompetent patient: case report and a minireview
Do you wish to request the book?
Trichosporon asahii causing subcutaneous mycoses in an immunocompetent patient: case report and a minireview
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trichosporon asahii causing subcutaneous mycoses in an immunocompetent patient: case report and a minireview
2022
Overview
Trichosporon
spp. are a constituent of the normal flora of humans that can cause both superficial and invasive infections, mainly in immunocompromised and immunocompetent hosts, respectively. Herein, we a report of
Trichosporon asahii
causing subcutaneous fungal infection (SFI) in an immunocompetent patient after carpal tunnel surgery. Although susceptible to fluconazole, the treatment of SFI failed even using high doses of this azole. The skin lesion improved following the administration of voriconazole. We conducted a literature minireview searching reports on SFI in immunocompetent patients to check for epidemiological, diagnostic, therapeutic, and outcome characteristics. A total of 32 cases were reported. Despite being uncommon, the clinical suspicion and early diagnosis of SFI in immunocompetent patients undergoing previous surgery are important. Our study indicated that the azoles are the most active antifungal agents against
Trichosporon
spp., except for fluconazole, and voriconazole can be considered the first therapeutic option.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Antifungal Agents - therapeutic use
/ Azoles
/ Biomedical and Life Sciences
/ Biopsy
/ Clinical Microbiology - Research Paper
/ Dermatomycoses - drug therapy
/ Diabetes
/ Flora
/ Fluconazole - therapeutic use
/ Fungi
/ Humans
/ Microbial Genetics and Genomics
/ Mycology
/ Mycosis
/ Patients
/ Surgery
/ Trichosporonosis - diagnosis
/ Trichosporonosis - drug therapy
